secwatch.observer — SEC 8-K summary
======================================

Issuer:     uniQure N.V. (QURE)
CIK:        0001590560
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001104659-25-055242
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

uniQure reaches FDA alignment on AMT-130 BLA for Huntington's disease; submission by Q1 2026
--------------------------------------------------------------------------------

- FDA supports cUHDRS as accelerated approval endpoint; primary analysis uses 3-year cUHDRS change vs propensity score-weighted ENROLL-HD external control.
- CMC validation: FDA agrees to use prior HEMGENIX knowledge, plus additional AMT-130 GMP batches and one PPQ batch; potency assay plan accepted pending qualification.
- BLA submission targeting Q1 2026 with request for priority review; pre-BLA meeting in Q4 2025; Phase I/II topline data in Q3 2025.
- Type B meetings held in Q1 and Q2 2025 on CMC and SAP; FDA aligned on statistical analysis plan including sensitivity analyses using TRACK-HD and PREDICT-HD datasets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590560/000110465925055242/0001104659-25-055242-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590560/000110465925055242/tm2516829d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-055242

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer